In the preclinical and early MCI phases (cohort 1), blood BD-tau followed CSF t-tau elevation, whereas in later MCI and dementia phases, blood BD-tau elevation was apparent regardless of CSF t-tau levels (cohort 3). The gene discussed is MAPT; the disease is dementia.